Trial Profile
A Single Centre, Single Dose, Open-label, Randomized, 2-part, 2-way Crossover Study to Determine the Bioequivalence of Levocetirizine Oral Disintegrating Tablet Given With Water and Without Water Compared to Levocetirizine Immediate Release Tablet in Healthy Japanese Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Jul 2023
Price :
$35
*
At a glance
- Drugs Levocetirizine (Primary) ; Levocetirizine (Primary)
- Indications Allergic rhinitis; Dermatitis; Perennial allergic rhinitis; Pruritus; Seasonal allergic rhinitis; Urticaria
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 13 Sep 2018 Status changed from recruiting to completed.
- 20 Jun 2018 New trial record